This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Bayer Pharmaceuticals.
Reference
Tamoschus D, et al. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Clinical Drug Investigation : 30 Mar 2017. Available from: URL: http://doi.org/10.1007/s40261-017-0514-3
Rights and permissions
About this article
Cite this article
Regorafenib a cost-effective option for GIST in Germany. PharmacoEcon Outcomes News 776, 30 (2017). https://doi.org/10.1007/s40274-017-3932-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3932-9